Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.

Paul MuntnerLama GhaziJenna JonesNafeesa DhalwaniBharat PoudelYing WenLigong ChenZhixin WangVera BittnerBethany KalichMichael E FarkouhMark WoodwardLisandro D ColantonioRobert S Rosenson

Published in: Advances in therapy (2024)

These data suggest approaches to increase persistence and adherence to PCSK9i mAb and ezetimibe should be implemented prior to or within 182 days following treatment initiation.

Keyphrases

electronic health record
low density lipoprotein
glycemic control
type diabetes
monoclonal antibody
machine learning
weight loss
data analysis